Animal experiments demonstrate for the first time that transplanted tumors release a chemical into the host’s bloodstream that causes the host to produce blood vessels to supply the tumor.… If such a factor can be identified in human cancers … it might be possible to prevent the vascularization of tumors. Since tumors above a certain small size require a blood supply to live, they might by this method be starved to death. — Science News, May 4, 1968
Update By the 1990s, starving tumors had become a focus of cancer research. Several drugs available today limit a tumor’s blood supply. But the approach can actually drive some cancer cells to proliferate, researchers have found. For those cancers, scientists have proposed treatments that open up tumors’ gnarled blood vessels, letting more oxygen through. Boosting oxygen may thwart some cancer cell defenses and promote blood flow — allowing chemotherapy drugs and immune cells deeper access to tumors (SN: 3/4/17, p. 24).
The world tracked the New Horizons’ spacecraft with childlike glee as it flew by Pluto in 2015. The probe provided the first ever close-up of the place that many of us grew up considering the ninth planet. Pluto revealed itself as a fascinating world, with a shifting surface (SN: 12/26/15, p. 16), a hazy atmosphere (SN Online: 10/15/15) and a heart of nitrogen ice (SN Online: 9/23/16). But the course of space exploration never did run smooth. In Chasing New Horizons, Alan Stern — New Horizons’ principal investigator and chief champion — and his coauthor, team member David Grinspoon, share their recollections of how a band of scrappy planetary scientists got a mission to the farthest reaches of the solar system off the ground. Over the course of a decade and a half, Stern and colleagues in the “Pluto Underground” fought first to get a Pluto mission taken seriously by NASA, then to keep it alive through budget woes, political battles, stiff competition from other mission proposals and outright cancellations.
Even if you followed the flyby closely and think you know this story, the book divulges details that will surprise you. Come for the sweeping tale of wonder and exploration; stay for the gaggle of planetary scientists celebrating on Bourbon Street once their mission finally got the green light.
Science News talked with Stern about the book, what it’s like to be “Mr. Pluto” and what’s next for New Horizons, which is currently in hibernation cruising through the Kuiper Belt. The interview that follows has been edited for length and clarity. SN: Almost half of the book is about the fight to get the New Horizons mission approved. Why was it important for you to focus on that? Stern: If you look at the 26-year span, from 1989 [the year the American Geophysical Union meeting devoted the first conference session to the subject of a Pluto mission] to 2015 when we got there, almost precisely half of that time was back and forth trying to get a mission to Pluto.
It’s rare for the public to get to see the behind the scenes of how difficult it is — how much competition there is, how many things come out of left field, how much scientists with a goal or objective in mind really have to have persistence to make it happen.
SN: You write that by the time the mission teams were being assembled, you were already known as Mr. Pluto. When did you start feeling like Mr. Pluto yourself?
Stern: Somewhere in the ʼ90s, when we were going through this maze of twists and turns to get a mission to Pluto. Every time we’d have a reversal, and I’d have to go fight for it again, I started to feel like I was putting on my Mr. Pluto hat.
I’m typecast that way now. You know, I’ve been on 29 different space missions, to almost every planet in the solar system. Only one of them was to Pluto, but that’s the one, maybe the only one, I’m known for. It’s like being on the cast of Gilligan’s Island, they only remember you for the one thing, no matter how much else you’ve done. Which is fine [laughs]. I love Pluto, no question, but it’s not like that’s all I did in the past three decades.
SN: What’s next for New Horizons?
Stern: We emerge from an almost six-month hibernation period on June 4. Our next flyby is taking place on New Year’s Eve and New Year’s Day with a small Kuiper Belt object that we’ve nicknamed Ultima Thule, which is a building block of planets like Pluto.
It’s going to just be spectacular, scientifically. And so our team is really up to our eyeballs in flyby planning and preparations.
SN: How long can the spacecraft keep going after that?
Stern: New Horizons has the fuel and power to go on for decades, and it’s very healthy. And there’s a lot more science to do in the Kuiper Belt. In fact, there is some science that the spacecraft is capable of doing that no other spacecraft can. There are some kinds of unique astrophysics that even the James Webb [Space Telescope, due to launch in 2020] and the Hubble can’t do, that we can do.
New Horizons is really is an amazing resource. There’s no other spacecraft planned to fly to these great distances again. So we want to make sure that science benefits to the maximum extent.
SN: There’s a scene in the book, right before the Pluto flyby, when a journalist asks how you’re going to feel at the end of the mission — will there be a sort of grief at the culmination of all this work. Now that you’re on the other side, how does it feel?
Stern: A lot of people in the mission team, as we were finally bearing down on Pluto, started to express that kind of concern. Frankly, we’d been so busy I didn’t have time to think philosophically about “what after.” I was thinking about catching up on my sleep, seeing my family more, what discoveries would we make. But I wasn’t thinking about, what do you do after your Apollo 11? What do you do after you’ve scaled your Everest?
As it turns out, a lot of those concerns just sort of washed away with the success of the flyby and the spectacular scientific discoveries at Pluto. Now I and other people on our team look back on it and say, “I was a part of something that really made a difference.” You can’t ask for much more than that.
Synthetic nanoparticles used to fight cancer could also heal sickly plants.
The particles, called liposomes, are nanosized, spherical pouches that can deliver drugs to specific parts of the body (SN: 12/16/06, p. 398). Now, researchers have filled these tiny care packages with fertilizing nutrients. The new liposomes, described online May 17 in Scientific Reports, soak into plant leaves more easily than naked nutrients. That allows the nanoparticles to give malnourished crops a more potent pick-me-up than the free-floating molecules in ordinary nutrient spray. Each liposome is a hollow sphere about 100 nanometers across, and is made of fatty molecules extracted from soybean plants. Once a plant leaf absorbs these nanoparticles, the liposomes spread to cells in the plant’s other leaves and its roots, where the fatty envelopes break down and release their molecular cargo. Researchers first exposed tomato plants to either liposomes packed with a rare earth metal called europium, or free-floating europium molecules. Europium doesn’t naturally exist in plants or soil, so it’s easy to trace how much of this element plants soaked up after treatment. Three days after exposure, plants treated with liposomes had absorbed up to 33 percent of the nanoparticles. Plants exposed to free-floating europium took in less than 0.1 percent of the molecules The researchers then spritzed iron- and magnesium-deficient tomato plants with either a standard spray containing iron and magnesium, or a solution containing liposomes packed with those nutrients. Two weeks later, the leaves on plants treated with free-floating nutrients were still tinged yellow and curled. Plants that received liposome treatment sported healthy, green leaves.
Avi Schroeder, a chemical engineer at the Israel Institute of Technology in Haifa, and colleagues don’t know exactly why liposomes are more palatable to plants than plain nutrients. But sprays that contain nutrient-loaded liposomes could help farmers rejuvenate frail plants more efficiently than existing mixtures, Schroeder says.
Liposome-based spray would need to be tested on a variety of vegetation before it could enter widespread use, says Ramesh Raliya, a nanobiotechnology researcher at Washington University in St. Louis not involved in the work. That’s because the pores on leaves where liposomes are assumed to enter plants can range from 50 to 150 nanometers across. If a plant’s pores are smaller than 100 nanometers, the liposomes can’t squeeze inside.
Mariya Khodakovskaya, a biologist at the University of Arkansas at Little Rock, is wary of the potential cost of this new technique. Fashioning liposomes is expensive. That’s not a problem for making liposome-based medication, which requires only a small amount of nanoparticles. But for any new agricultural practice to take root, she says, “it has to be massive, and it has to be cheap.”
E. coli has a type and it isn’t pretty. The bacterium is more likely to cause severe diarrhea in people with type A blood.
An illness-causing strain of E. coli secretes a protein that gloms onto the sugar molecules that decorate type A blood cells, but not type B or O cells. These sugar molecules also decorate cells lining the intestines of people with type A blood and appear to provide a handle for the bacterium to latch onto before injecting its diarrhea-causing toxins, researchers report May 17 in the Journal of Clinical Investigation. There were hints that blood type was linked to the severity of E. coli infection. But a clear connection was lacking until now, says a team led by researchers at Washington University School of Medicine in St. Louis.
Collaborators at Johns Hopkins University gave 106 healthy volunteers water laced with a strain of E. coli isolated from a person in Bangladesh with severe diarrhea. Within five days, 81 percent of the type A or AB volunteers developed moderate to severe diarrhea compared with roughly half the people with blood types O or B. (Everyone received antibiotics to clear the bacterium).
This discovery suggests that a vaccine targeting the bacterial protein — which is found in many E. coli strains — could be effective. That could help not only travelers but also children in the developing world, where repeated infections are linked to malnutrition and stunted growth. E. coli isn’t the only microbe that can cause severe diarrhea, though, making good hygiene — washing hands and purifying water — still the best defense.
Ancient colonizers of the Americas could have traveled down Alaska’s Pacific coast in canoes or other sea vessels around 17,000 years ago, a new study finds.
At that time, toward the end of the last ice age, glaciers had just receded from a cluster of southern Alaskan islands, say geologist Alia Lesnek of the University at Buffalo in New York and colleagues. Life-supporting habitats appeared soon after the ice melted, the scientists report May 30 in Science Advances. The study is the latest to weigh in on the debate over how humans spread into the New World after arriving from Asia and reaching as far as Florida and South America by 14,500 years ago ( SN: 6/11/16, p. 8 ; SN: 12/26/15, p. 10 ). Previous work has hinted that an inland, ice-free corridor from Alaska through what’s now British Columbia and into the United States may not have contained enough vegetation and wildlife to enable human travel before around 12,600 years ago ( SN Online: 8/10/16 ). New geologic evidence supports the idea of a coastal route, though Lesnek’s team found no human bones or artifacts on the islands. Measures of chemicals that accumulate in rock due to cosmic radiation once glaciers retreat provided age estimates for when four Alaskan islands lost their ice coat. An open pathway for coastal travelers probably existed along the entire southeastern Alaskan coast roughly 17,000 years ago, the scientists say. Radiocarbon dates for a ringed seal’s remains found on a southern Alaskan island indicate that the seal lived about 17,000 years ago, suggesting the area became habitable soon after glaciers left.
A little animal that washed out to sea 240 million years ago off the coast of what’s now Italy turns out to be the oldest known fossil of a lizard.
The identification pushes back the fossil record of snakes and lizards by about 75 million years, says Tiago Simões of the University of Alberta in Edmonton, Canada. He and colleagues used observations of the fossil, called Megachirella wachtleri, and of related living and extinct species plus genetic data to reconstruct the evolutionary history of squamates, the reptile group that today includes snakes and lizards, the researchers report in the May 31 Nature. “Understanding lizard and snake evolution has been a constant problem in paleontology,” says vertebrate paleontologist Stephanie Pierce of Harvard University who worked on the issue years ago but wasn’t involved in the new study. The trouble comes largely from a lack of relevant fossils, she says. That dearth isn’t just because little animals don’t fossilize as readily as big ones do. “Things like giant dinosaurs — they’re pretty easy to spot,” she says. “But if you’re looking for something that can fit in the palm of your hand, that makes it very challenging.” A collector found M. wachtleri almost 20 years ago in a part of the Italian Alps that had once been underwater. But researchers didn’t categorize it as a full member of the squamate branch of reptiles, until now. The sole specimen is partly embedded in rock, which obscured some of the creature’s telltale features. Now a CT scan has revealed previously unknown squamate details of its palate, braincase, limbs and shoulder, Simões says. M. wachtleri was a small, terrestrial animal with teeth appropriate for snapping up insects, he says. Yet a catastrophe such as a tropical storm apparently swept it out to sea along with masses of leaves.
Besides taking a closer look at M. wachtleri, Simões and some colleagues traveled to 17 countries from Brazil to China to reexamine the other known squamate fossils. Combining all of the new fossil measurements with DNA data, the researchers reconstructed the evolutionary tree of squamates. Among the new insights: Geckos appear to be the most ancient of still-surviving lizards, the team found. And iguanas, a hard-to-place group on the tree, have a more recent origin than some other studies have found.
“The picture is coming together,” says study coauthor Oksana Vernygora, an evolutionary biologist also at the University of Alberta.
Previously, the oldest known squamate fossils dated back about to 168 million years ago. Adding M. wachtleri to the mix means that the squamates are so ancient that they arose before the mass extinction at the end of the Permian Period 252 million years ago, notes herpetologist and evolutionary biologist Jeff Streicher of the Natural History Museum in London who was not involved in the study. That cataclysm came the closest (yet) to wiping out life on Earth. How the ancestors of modern lizards and snakes made it is still a matter of debate.
The spacecraft fire that killed three Apollo astronauts and rocked the space agency a year and a half ago is still being felt.… Last week, after a series of delays … a major milestone was finally reached: the first manned tests of an Apollo spacecraft to include all the new equipment and safeguards incorporated since the fire. — Science News, June 8, 1968.
Update Since that lunar program reboot, hundreds of NASA astronauts have made it to space, and 12 astronauts have walked on the surface of the moon. After NASA retired the U.S. Space Shuttle program in 2011, American astronauts have had to rely on Russia’s Soyuz spacecraft to reach the International Space Station (SN: 6/11/16, p. 4). Once again, U.S. spacecraft, from SpaceX and Boeing, are planned to take American astronauts into space, but delays have pushed those efforts back to late 2019 and 2020.
Stay younger, longer. Great idea. But direct-to-consumer test kits that promise to gauge a person’s biological age by analyzing a drop of blood are not worth the $100 or so investment, says oncologist Mary Armanios. The tests measure the length of telomeres, the bits of DNA that cap and protect the ends of chromosomes. But the consumer tests are unreliable and can be misinterpreted, Armanios says.
“These kinds of tests can do harm, suggesting there is something wrong when there isn’t,” says the Johns Hopkins School of Medicine researcher, who uses a clinical test of telomere length to diagnose and treat people with certain rare disorders. Armanios gets calls from people who panic when they get their results from consumer tests. One man in his 40s was told his telomeres were those of an 80-year-old. He sold his house and quit work to make the most of the short time he was convinced he had left. Worse, she says, because he was under the misguided impression that surgeries shorten telomeres, he had decided to delay removal of a precancerous skin spot.
Armanios trained in the lab of Carol Greider, who shared the 2009 Nobel Prize in physiology or medicine for discovering telomerase, the enzyme that controls telomere lengthening (SN: 10/24/09, p. 14). Today Armanios is clinical director of the telomere center at Johns Hopkins.
There is a wide range of “normal” when it comes to telomere length. Work by her team and others has shown that cells don’t stop dividing or die because of telomere shortening unless the ends get very short, far from the median.
Yet, commercial testing companies will label clients as older than their birthday suggests if their telomeres are anywhere shorter than the median. Longer means younger. But excessively long telomeres are not a guarantee of a long life and may be associated with higher cancer risk.
The test many consumer companies use, quantitative polymerase chain reaction, or qPCR, has a 20 percent variability rate — tests on different days can yield different answers, studies by Armanios and others have shown. The clinical test Armanios’ group uses is flow cytometry and fluorescent in situ hybridization, or flow-FISH, which has a lower, 5 percent, variability rate. The researchers use the more precise test to study a small group of disorders united by telomere defects. For two of the illnesses, treatment decisions can change based on clinical telomere testing. A hereditary form of aplastic anemia, a failure of the bone marrow to make blood cells, can be treated with a stem cell transplant with immune suppression. People whose telomeres are short need less immune suppression with the transplant. In a study by Armanios and colleagues in the March 6 Proceedings of the National Academy of Sciences, telomere testing flagged nine of 38 patients who required a gentler approach. Likewise, patients with short telomeres who are receiving lung transplants for idiopathic pulmonary fibrosis should get low immune suppression. In fact, traditional levels can be lethal. With this knowledge, the transplant can be done more safely.
“The telomere belongs in the clinic,” Armanios says, “and should not be used as a form of molecular palm reading.”
Air pollution caused 3.2 million new cases of diabetes worldwide in 2016, according to a new estimate.
Fine particulate matter, belched out by cars and factories and generated through chemical reactions in the atmosphere, hang around as haze and make air hard to breathe. Air pollution has been linked to chronic conditions such as heart disease and diabetes (SN: 9/30/17, p. 18), but this study is one of the first attempts to quantify the connection for diabetes. Researchers tracked 1.7 million U.S. veterans for almost a decade to assess their risk of developing diabetes. They also used data from global studies on diabetes risk, as well as air quality data from the U.S. Environmental Protection Agency and NASA, to create equations that analyzed the connection between air pollution exposure and diabetes globally.
The new estimate, reported in July in The Lancet Planetary Health, holds air pollution responsible for about 14 percent of new cases of diabetes worldwide. Factors such as genetics, weight, activity level and diet also influence the risk of the disease, which is on the rise globally. (The World Health Organization estimates that 422 million people now live with type 2 diabetes — up from 108 million in 1980.)
The burden isn’t the same around the globe: Unsurprisingly, countries with high pollution levels, such as Pakistan, India and China, also have especially high rates of air pollution-linked diabetes. The United States, which now has comparatively clean air, is also high on the list.
Forget all the ridicule heaped on treadmill-running shrimp.
About 80 percent of U.S. adults think that government spending on medical research, engineering and technology, and basic science usually leads to meaningful advances, a new survey from the Pew Research Center shows. The nonprofit, nonpartisan research organization queried 2,537 people from April 23 to May 6.
No matter where they fell on the political spectrum, a majority of Republicans and Democrats shared that view. Of liberal Democrats surveyed, 92 percent said government investments in basic scientific research “usually pay off in the long run.” Of conservative Republicans, 61 percent agreed. That general agreement broke down when it came to private versus government spending. Two-thirds of conservative Republicans said that private investment alone would be enough to see that scientific progress is made, compared with 22 percent of liberal Democrats.
Surveys in 2017, 2014 and 2009 by Pew also found similar support among Americans for spending taxpayer dollars on science.
Some seemingly silly government-funded experiments, such as the exercising shrimp, have been singled out by politicians and others in the past as examples of wasteful spending. But appearances can be misleading. Putting the crustaceans through their paces, for example, was part of a larger project studying infection in farmed shrimp in hopes of finding treatments.
